Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

Campus

Payor

Login
Registration

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Asthma
Atopic Dermatitis
Chronic Obstructive Pulmonary Disease
Chronic Spontaneous Urticaria
Diabetes
Eosinophilic Esophagitis
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo Nodularis
Rare Diseases
Transplant
Bullous Pemphigoid

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Multiple Sclerosis
Smoldering Neuroinflammation

Vaccines
Influenza
RSV
Mass Gathering

Patient Support
Asthma
Atopic Dermatitis
Cardiovascular
Diabetes

Rare Diseases
2024

Product
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Nexviazyme
Renvela®
Tavanic®
Xatral®
Qfitlia®

Aldurazyme®
Dosing Calculator
Expert's Videos

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience

Cablivi®
aTTP Sphere Digital Case Library

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Dupixent Asthma
Eosinophilic Esophagitis
Prurigo Nodularis
Atopic Dermatitis
Nasal Polyps
Dupixent® COPD
Dupixent® Chronic Spotaneous Urticaria (CSU)

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function
FASTEX FAbry Stabilization Index

Plavix®
Tolerability

Praluent®

Praluent®
LDL-C Control
Tolerability
Patients at CV Risk
Starting Praluent®

It's Praluent of Course
Of Course
What is PRALUENT®?
Why choose PRALUENT®?
How to use PRALUENT®?

Rezurock®
Safety
Mechanism of Action
Dosing

Impact of cVGHD
Challenges of Disease Progression

Efficacy
Efficacy Data

Sarclisa®
Sarclisa +VRd
MoA
Dosage
Clinical Resources

Sarclisa KD
Sarclisa + Kd (IKEMA) Efficacy
Sarclisa + Kd (IKEMA) Safety

Sarclisa PD
Sarclisa + Pd (ICARIA-MM) + Efficacy
Sarclisa + Pd (ICARIA-MM) + Safety

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua®
Soliqua Safety®
Soliqua Simplicity®
Soliqua Data Set®
Soliqua Guidelines®
Soliqua Easy Start®
Soliqua SoliD®

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Xenpozyme®
Dose Escalation Phase of Olipudase

Zympass®
Tolerability
Usage

Campus

Payor

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Asthma
Atopic Dermatitis
Chronic Obstructive Pulmonary Disease
Chronic Spontaneous Urticaria
Diabetes
Eosinophilic Esophagitis
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo Nodularis
Rare Diseases
Transplant
Bullous Pemphigoid

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Multiple Sclerosis
Smoldering Neuroinflammation

Vaccines
Influenza
RSV
Mass Gathering

Patient Support
Asthma
Atopic Dermatitis
Cardiovascular
Diabetes

Rare Diseases
2024

Product
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Nexviazyme
Renvela®
Tavanic®
Xatral®
Qfitlia®

Aldurazyme®
Dosing Calculator
Expert's Videos

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience

Cablivi®
aTTP Sphere Digital Case Library

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Dupixent Asthma
Eosinophilic Esophagitis
Prurigo Nodularis
Atopic Dermatitis
Nasal Polyps
Dupixent® COPD
Dupixent® Chronic Spotaneous Urticaria (CSU)

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function
FASTEX FAbry Stabilization Index

Plavix®
Tolerability

Praluent®

Praluent®
LDL-C Control
Tolerability
Patients at CV Risk
Starting Praluent®

It's Praluent of Course
Of Course
What is PRALUENT®?
Why choose PRALUENT®?
How to use PRALUENT®?

Rezurock®
Safety
Mechanism of Action
Dosing

Impact of cVGHD
Challenges of Disease Progression

Efficacy
Efficacy Data

Sarclisa®
Sarclisa +VRd
MoA
Dosage
Clinical Resources

Sarclisa KD
Sarclisa + Kd (IKEMA) Efficacy
Sarclisa + Kd (IKEMA) Safety

Sarclisa PD
Sarclisa + Pd (ICARIA-MM) + Efficacy
Sarclisa + Pd (ICARIA-MM) + Safety

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua®
Soliqua Safety®
Soliqua Simplicity®
Soliqua Data Set®
Soliqua Guidelines®
Soliqua Easy Start®
Soliqua SoliD®

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Xenpozyme®
Dose Escalation Phase of Olipudase

Zympass®
Tolerability
Usage

Login
Registration

Epilepsy Do’s and Don’ts

Related articles

MAT-BH-2300335/V1/May 2023

Campus

Back to top

Legal notice Cookie policy Privacy policy Sitemap Change country

© Sanofi 2004- - All rights reserved

MAT-AE-2100444/v7/Jan 2024

SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE,

Tel.: +971 4 550 3600 | Fax: +971 4 5521050

For further medical information, please contact: For UAE 800 MEDICAL Toll-Free Number or email: medical-information.gulf@sanofi.com

To report an adverse event: please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com
To report any product technical complaints, kindly contact Email: quality.greatergulf@sanofi.com

leave-site-modal-text

You Will Now Be Leaving the Site

By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.